ABMT (Advanced BioMedical Technologies) Beneish M-Score: 0.00 (As of Jun. 28, 2026)


What is Advanced BioMedical Technologies Beneish M-Score?

Advanced BioMedical Technologies ABMT Beneish M-Score is 0.00 as of Jun. 28, 2026.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

The historical rank and industry rank for Advanced BioMedical Technologies's Beneish M-Score or its related term are showing as below:

During the past 13 years, the highest Beneish M-Score of Advanced BioMedical Technologies was 0.00. The lowest was 0.00. And the median was 0.00.

Advanced BioMedical Technologies Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Advanced BioMedical Technologies's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Advanced BioMedical Technologies Beneish M-Score Chart

Advanced BioMedical Technologies Annual Data
Trend Oct11 Oct12 Oct13 Oct14 Oct15 Oct16 Oct17 Oct18 Oct19 Oct20
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -8.31

Advanced BioMedical Technologies Quarterly Data
Oct16 Jan17 Apr17 Jul17 Oct17 Jan18 Apr18 Jul18 Oct18 Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -8.31 -16.24 -14.20 -11.61

ABMT vs VYCO, ADMT, THMO: Beneish M-Score Comparison

For the Medical Devices subindustry, Advanced BioMedical Technologies's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Advanced BioMedical Technologies Beneish M-Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Advanced BioMedical Technologies's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Advanced BioMedical Technologies's Beneish M-Score falls into.


Advanced BioMedical Technologies Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Advanced BioMedical Technologies for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * +0.528 * +0.404 * +0.892 * +0.115 *
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * +4.679 * -0.327 *
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Jul21) TTM:Last Year (Jul20) TTM:
Total Receivables was $0.05 Mil.
Revenue was 0 + 0 + 0.047 + 0.062 = $0.11 Mil.
Gross Profit was 0 + 0 + 0.037 + 0.044 = $0.08 Mil.
Total Current Assets was $0.24 Mil.
Total Assets was $0.40 Mil.
Property, Plant and Equipment(Net PPE) was $0.15 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.08 Mil.
Selling, General, & Admin. Expense(SGA) was $0.24 Mil.
Total Current Liabilities was $8.58 Mil.
Long-Term Debt & Capital Lease Obligation was $0.00 Mil.
Net Income was -0.199 + -0.189 + -0.172 + -0.193 = $-0.75 Mil.
Non Operating Income was -0.005 + 0.004 + -0.006 + -0.008 = $-0.02 Mil.
Cash Flow from Operations was -0.081 + -0.147 + -0.515 + 0.752 = $0.01 Mil.
 Total Receivables was $0.04 Mil.
Revenue was 0.001 + 0 + 0.061 + 0.012 = $0.07 Mil.
Gross Profit was 0 + 0 + 0.027 + 0.004 = $0.03 Mil.
Total Current Assets was $0.13 Mil.
Total Assets was $0.28 Mil.
Property, Plant and Equipment(Net PPE) was $0.15 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.02 Mil.
Selling, General, & Admin. Expense(SGA) was $0.15 Mil.
Total Current Liabilities was $7.27 Mil.
Long-Term Debt & Capital Lease Obligation was $0.01 Mil.

1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(0.047 / 0.109) / (0.035 / 0.074)
=0.431193 / 0.472973
=

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(0.031 / 0.074) / (0.081 / 0.109)
=0.418919 / 0.743119
=

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (0.243 + 0.154) / 0.397) / (1 - (0.13 + 0.152) / 0.282)
=0 / -0
=

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=0.109 / 0.074
=

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0.018 / (0.018 + 0.152)) / (0.082 / (0.082 + 0.154))
=0.105882 / 0.347458
=

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(0.235 / 0.109) / (0.154 / 0.074)
=2.155963 / 2.081081
=

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((0 + 8.579) / 0.397) / ((0.01 + 7.265) / 0.282)
=21.609572 / 25.797872
=

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-0.753 - -0.015 - 0.009) / 0.397
=-1.881612

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of 0.00 mean?
Advanced BioMedical Technologies (ABMT) has a Beneish M-Score of 0.00 as of Jun. 28, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Advanced BioMedical Technologies and its competitors.
Is Advanced BioMedical Technologies' Beneish M-Score too high?
Advanced BioMedical Technologies' current Beneish M-Score is 0.00.
How does Advanced BioMedical Technologies' Beneish M-Score compare to VYCO and ADMT?
Advanced BioMedical Technologies' Beneish M-Score of 0.00 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Medical Devices & Instruments company?
A good Beneish M-Score depends on the Medical Devices & Instruments industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Advanced BioMedical Technologies and its competitors. Advanced BioMedical Technologies's current Beneish M-Score is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Advanced BioMedical Technologies stock overvalued right now?
Advanced BioMedical Technologies (ABMT) has a current Beneish M-Score of 0.00. The current Beneish M-Score is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Advanced BioMedical Technologies (ABMT), the current Beneish M-Score is 0.00 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Advanced BioMedical Technologies Business Description

Address 535 Fifth Avenue, 4th Floor, New York, NY, USA, 10017
Advanced BioMedical Technologies Inc is engaged in designing, developing, manufacturing, and the planned future marketing of self-reinforced, re-absorbable, biodegradable internal fixation devices. The company manufactures its products using Polyamide, and it is used in a variety of applications, which include orthopaedic trauma, sports-related medical treatment, cartilage injuries, and reconstructive dental procedures. Its Polyamide products include screws, rods, and binding wires consisting of enhanced fibres and high molecular polymers, which are designed to facilitate quick healing of complex fractures in many areas of the human skeletal system.